Literature DB >> 16142360

5-aza-2'-deoxycytidine sensitizes hepatoma and pancreatic cancer cell lines.

Tatsuo Kanda1, Motohisa Tada, Fumio Imazeki, Osamu Yokosuka, Keiichi Nagao, Hiromitsu Saisho.   

Abstract

Hepatocellular carcinoma (HCC) and pancreatic cancer are at the forefront of chemotherapy-resistant tumors with poor prognosis. Even with innovative treatment regimens, response rates remain low and the duration of response is short. We examined whether the suppression of DNA methylation was capable of enhancing the sensitivity of hepatoma and pancreatic cancer cell lines to 5-fluorouracil (5-FU). 5-aza-2'-deoxycytidine (5-aza-dC) at 2 microM, a specific DNA methylation inhibitor, did not induce cell death in Huh-7 with or without HCV, HLE, HepG2 and MIA PaCa-2 cells. However, a combination of 5-aza-dC with 5-FU showed a reduction in cell viability and induction of apoptosis in these cell lines to a greater degree than with 5-FU only. These findings underline the fact that DNA methylation plays a key role in conferring chemoresistance to hepatoma and pancreatic cancer, and the combination of DNA methylation inhibitor with chemotherapy could be a novel and highly effective tool for future targeted therapy of chemoresistant tumors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16142360

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  13 in total

1.  Demethylating agent 5-aza-2-deoxycytidine enhances susceptibility of breast cancer cells to anticancer agents.

Authors:  Sameer Mirza; Gayatri Sharma; Pranav Pandya; Ranju Ralhan
Journal:  Mol Cell Biochem       Date:  2010-05-09       Impact factor: 3.396

2.  Reduction of pancreatic acinar cell tumor multiplicity in Dnmt1 hypomorphic mice.

Authors:  Shirley Oghamian; Nicole M Sodir; Muhammad U Bashir; Hui Shen; Andrea E Cullins; Cindy A Carroll; Pratima Kundu; Darryl Shibata; Peter W Laird
Journal:  Carcinogenesis       Date:  2011-03-01       Impact factor: 4.944

3.  Phase I Study of Epigenetic Priming with Azacitidine Prior to Standard Neoadjuvant Chemotherapy for Patients with Resectable Gastric and Esophageal Adenocarcinoma: Evidence of Tumor Hypomethylation as an Indicator of Major Histopathologic Response.

Authors:  Bryan J Schneider; Manish A Shah; Kelsey Klute; Allyson Ocean; Elizabeta Popa; Nasser Altorki; Michael Lieberman; Andrew Schreiner; Rhonda Yantiss; Paul J Christos; Romae Palmer; Daoqi You; Agnes Viale; Pouneh Kermani; Joseph M Scandura
Journal:  Clin Cancer Res       Date:  2016-11-10       Impact factor: 12.531

4.  Involvement of interleukin-6 and androgen receptor signaling in pancreatic cancer.

Authors:  Kohichiroh Okitsu; Tatsuo Kanda; Fumio Imazeki; Yutaka Yonemitsu; Ratna B Ray; Chawnshang Chang; Osamu Yokosuka
Journal:  Genes Cancer       Date:  2010-08

5.  Combined inhibition of Dnmt and mTOR signaling inhibits formation and growth of colorectal cancer.

Authors:  Yan-Jie Zhang; Shu-Liang Zhao; Xiao-Qing Tian; Dan-Feng Sun; Hua Xiong; Qiang Dai; Xiao-Qiang Li; Jing-Yuan Fang
Journal:  Int J Colorectal Dis       Date:  2009-02-20       Impact factor: 2.571

Review 6.  DNA methylation, microRNAs, and their crosstalk as potential biomarkers in hepatocellular carcinoma.

Authors:  Sumadi Lukman Anwar; Ulrich Lehmann
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

Review 7.  Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight.

Authors:  K Lohitesh; Rajdeep Chowdhury; Sudeshna Mukherjee
Journal:  Cancer Cell Int       Date:  2018-03-20       Impact factor: 5.722

8.  Epigenetic control of metastasis-associated protein 1 gene expression by hepatitis B virus X protein during hepatocarcinogenesis.

Authors:  M-H Lee; H Na; T-Y Na; Y-K Shin; J-K Seong; M-O Lee
Journal:  Oncogenesis       Date:  2012-09-03       Impact factor: 7.485

Review 9.  DNA Methylation and Chromatin Remodeling: The Blueprint of Cancer Epigenetics.

Authors:  Dipanjan Bhattacharjee; Smita Shenoy; Kurady Laxminarayana Bairy
Journal:  Scientifica (Cairo)       Date:  2016-03-28

10.  Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin.

Authors:  Michael J Overman; Van Morris; Helen Moinova; Ganiraju Manyam; Joe Ensor; Michael S Lee; Cathy Eng; Bryan Kee; David Fogelman; Rachna T Shroff; Thomas LaFramboise; Thibault Mazard; Tian Feng; Stanley Hamilton; Bradley Broom; James Lutterbaugh; Jean-Pierre Issa; Sanford D Markowitz; Scott Kopetz
Journal:  Oncotarget       Date:  2016-10-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.